Isogen Biosolutions B.V. is now Ocimum Biosolutions B. V.
News Aug 13, 2008
Isogen Biosolutions B. V. has rebranded itself as Ocimum Biosolutions B. V. The aim of the rebranding exercise is to tap the emerging opportunities and need for globalized solutions in Genomics.
This represents a significant milestone in company’s history as the company hones its position as the premier integrated global genomics solutions provider, the company says.
Synthetic DNA oligonucleotides now have wide spectrum of applications ranging from being used in fundamental research, as diagnostic reagents to discovery of pharmaceutical compounds.
The organization derives its name from Ocimum sanctum, which is considered to be an allude to purity. The value it brings to the medical world captures the essence of all genomes and species, which has made so much of a difference to the post-genomic era. Ocimum provides quality solutions spanning across the genomics space and partners with global organizations in the pursuit of improved and affordable healthcare.
“We now partner with global organizations and groups in their discovery endeavors from as early as basic research all the way up to clinical validations and target discovery. This announcement signifies our wide repertoire of offerings in genomics space. This makes it an integral part of our genomics business model,” says Anuradha Acharya, CEO of Ocimum Biosolutions.
In a new study in cells, University of Illinois researchers have adapted CRISPR gene-editing technology to cause the cell’s internal machinery to skip over a small portion of a gene when transcribing it into a template for protein building. This gives researchers a way not only to eliminate a mutated gene sequence, but to influence how the gene is expressed and regulated.